The FDA has approved the first once-daily, quaternary ammonium, anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease.
As determined by process-of-care measurement, adverse event occurrence, and patient satisfaction, quality of care is compromised by infection control procedures.
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
There is an association between long-distance air flights and venous thromboembolism, but the role of traditional risk factors and prophylactic measures requires more study.
Sleep and headache have a long and complex relationship. Morning (or awakening) headache has been linked to sleep disorders, especially obstructive sleep apnea syndrome, but this association is controversial.
It appears safe to conclude that patients with mild-to-moderate angina can be safely managed with continued medical therapy, but percutaneous coronary intervention is certainly indicated and appropriate if anginal symptoms are not controlled by maximum, aggressive medical management.
Did the ephedra ban mark a new era of dietary supplement regulation at the FDA? Altern Med Alert 224;7(8):S1-S2.
Greenfield RH. Manipulative therapy for shoulder pain. Altern Med Alert 2004;7(12):144.
